Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America

PR Newswire

PLAINSBORO, N.J.and BAGSVÆRD, Denmark, Jan. 5, 2026

OASIS 4 Results
		Wegovy pill 25 mg^®	Placebo
¹	If all patients stayed on treatment (Trial product estimand*)	~17%	~3%
¹	Analysis of all patients regardless of if they stayed on treatment (Treatment policy estimand**)	~14%	~2%

Media:

+1 609 917 0632Liz Skrbkova(US)

USMediaRelations@novonordisk.com

+45 3079 9289Globalmedia@novonordisk.comAmbre James-Brown (Global)

Investors:

Frederik Taylor Pitter (US)

+1 609 613 0568fptr@novonordisk.com

+45 3075 5956jrde@novonordisk.comJacob Martin Wiborg Rode (Global)

Sina Meyer (Global)

+45 3079 6656azey@novonordisk.com

+45 3079 1471Christoffer Sho Togo Tullin (Global)

cftu@novonordisk.com

mxun@novonordisk.comMax Ung (Global)

Alex Bruce (Global)

+45 34 44 26 13axeu@novonordisk.com

Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide 25 mg in adults with overweight or obesity. N Engl J Med
Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: December 2025. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.html
Wegovy^®
IQVIA LAAD Rx for the period of June 2021 to July 2024.
Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study.Obesity
Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation.Obes Rev
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity.Endocr Pract
Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: December 2025. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html

© 2026 Novo Nordisk All rights reserved. US25SEMO02598 January 2026

pill was approved on December 22, 2025 and is used with a reduced calorie diet and increased physical activity for adults with obesity, or with overweight who also have weight-related medical problems, to help them lose weight and keep it off.PLAINSBORO, N.J.and BAGSVÆRD, DenmarkJan. 5, 2026GLP-1^®²^®³

"We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them. For many of them, that wait is over as we can now offer the powerful efficacy of WegovyGLP-1^®^®^®

WegovyGLP-1^®^®⁴^®^*1^®^**1

With once-daily oral dosing, Wegovy^®

For Wegovy^®¹

In OASIS 4, common adverse reactions were similar to those previously seen in clinical trials with Wegovy^®¹

Novo Nordisk continues to pursue innovative delivery models and strategic collaborations to meet people where they are, reaching more patients in more ways. This is designed to help patients obtain authentic, FDA-approved medicines and avoid potentially unsafe, unapproved alternatives. Wegovy^®^®

Wegovy^®^®^®^†

Wegovywww.Wegovy.com^®³^®

Pay as little as $25, subject to a maximum savings of $100/month. Government beneficiaries excluded. Novo Nordisk reserves the right to modify or cancel this program at any time. See WegovyTerms.com for full terms.

^*^**^†

pill is also indicated to reduce the risk of major adverse cardiovascular events (MACE) such as death, heart attack, or stroke in adults with overweight or obesity and established cardiovascular disease.About Wegovy

^®GLP-1^®^®³

The FDA approval of Wegovy^®^®^**^®^*^®¹

Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.About obesity

^5-7^5,7^1,8

(semaglutide) tablets 25 mg are prescription medicines used with a reduced calorie diet and increased physical activity to: What is Wegovy^®?^®^®

Wegovy^®

Wegovy^®GLP-1

It is not known if Wegovy^®

Important Safety Information

What is the most important information I should know about Wegovy^®?Wegovy^®may cause serious side effects, including:

Do not use Wegovy^®if:

Before using Wegovy^®, tell your healthcare provider if you have any other medical conditions, including if you:

slows stomach emptying and can affect medicines that need to pass through the stomach quickly. Tell your healthcare provider about all the medicines you take,^®^®^®

What are the possible side effects of Wegovy^®?Wegovy^®may cause serious side effects, including:

nausea, diarrhea, vomiting, constipation, stomach (abdomen) pain, headache, tiredness (fatigue), upset stomach, dizziness, feeling bloated, belching, low blood sugar in people with type 2 diabetes, gas, stomach flu, heartburn, and runny nose or sore throat.The most common side effects of Wegovy^®may include:

Please click here for Prescribing Information including Boxed Warning and Medication Guide for Wegovy^®. 

About Novo Nordisk

Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com Facebook Instagram X

Contacts for further information

References:

View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-now-broadly-available-across-america-302652205.html

SOURCE NOVO NORDISK INC.

Average weight loss of ~17% if all patients stayed on treatment* with Wegovy^®¹
Starting dose of Wegovy^®
Wegovy^®^®

reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight.
help adults with obesity, or some adults with excess weight (overweight) who also have weight-related medical problems to lose weight and keep the weight off.

to reduce the risk of major cardiovascular events (death, heart attack, or stroke) in people under 18 years
to help children under 12 years of age lose weight and keep the weight off

will cause thyroid tumors or a type of thyroid cancer called medullary thyroid carcinoma (MTC) in peoplePossible thyroid tumors, including cancer.^®^®^®
Do not use Wegovy^®

you or any of your family have ever had a type of thyroid cancer called medullary thyroid carcinoma (MTC) or if you have an endocrine system condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
you have had a serious allergic reaction to semaglutide or any of the ingredients in Wegovy^®"What are the possible side effects of Wegovy?"^®^®

have or have had problems with your pancreas or kidneys
have type 2 diabetes and a history of diabetic retinopathy
have or have had depression, suicidal thoughts, or mental health issues
are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation)
are pregnant or plan to become pregnant. Wegovy^®^®
are breastfeeding or plan to breastfeed. Breastfeeding is not recommended during treatment with Wegovy^®^®

and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your backinflammation of your pancreas (pancreatitis).^®
may cause gallbladder problems, including gallstones. Some gallstones may need surgery. Call your healthcare provider if you have symptoms, such as pain in your upper stomach (abdomen), fever, yellowing of the skin or eyes (jaundice), or clay-colored stoolsgallbladder problems.^®
. Signs and symptoms of low blood sugar may include dizziness or light-headedness, blurred vision, anxiety, irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, fast heartbeat, or feeling jitteryincreased risk of low blood sugar (hypoglycemia), especially those who also take medicines for diabetes such as insulin or sulfonylureas.^®
Diarrhea, nausea, and vomiting may cause a loss of fluids (dehydration), which may cause kidney problems. It is important for you to drink fluids to help reduce your chance of dehydration. Tell your healthcare provider right away if you have nausea, vomiting, or diarrhea that does not go awaydehydration leading to kidney problems.
. Tell your healthcare provider if you have stomach problems that are severe or will not go awaysevere stomach problems.^®
and get medical help right away, if you have any symptoms of a serious allergic reaction, including swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or very rapid heartbeatserious allergic reactions.^®
Tell your healthcare provider if you have changes in vision during treatment with Wegovychange in vision in people with type 2 diabetes.^®
can increase your heart rate while you are at rest. Tell your healthcare provider if you feel your heart racing or pounding in your chest and it lasts for several minutesincreased heart rate^®
You should pay attention to any mental changes, especially sudden changes in your mood, behaviors, thoughts, or feelings. Call your healthcare provider right away if you have any mental changes that are new, worse, or worry youdepression or thoughts of suicide.
before you are scheduled to have surgery or other proceduresfood or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sleepiness (deep sedation).^®^®